Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#4589 Clinical efficacy of RLT to assess OS and PFS using 177Lu DOTATATE, 90Y DOTATATE, and a mixture of both in patients with advanced, unresectable, progressive rectal NET – A retrospective analysis

Introduction: Retrospective, single-arm, open-label, case series study evaluating the efficacy of different types of radioligand therapy (RLT): 177Lu, 90Y DOTATATE, or mix of both used in advanced, unresectable progressive rectal NETG1/G2.

Conference:

Presenting Author: Ćwikła J

Authors: Kolasińska-Ćwikla A, Sankowski A, Pałucki J, Sekelcka N, Ćwikła J,

Keywords: Rectal Neuroendocrine Tumour, SST Receptor, Radioligand Therapy (RLT),

#3833 Evaluation of PFS and OS in patients with sporadic, advanced, unresectable, well-differentiated pancreatic neuroendocrine tumors (NET) treated initially with Lanreotide AG and methods of further treatment approaches after progression real-world data

Introduction: .

Conference:

Presenting Author: Kolasińska-Ćwikła A

Authors: Kolasińska-Ćwikła A, Lewczuk-Myślicka A, Bednarczuk T, Osowiecka K, Słoniewska A,

Keywords: advanced NET, non-resectable pancreatic neuroendocrine tumor, Lanreotide therapy, real word data set,

#3826 Prognostic value of the neutrophil/lymphocyte ratio (NLR) in advanced, non resectable, progressive pancreatic and midgut NET after combine therapy using Lu-177 DOTATOC and CAPTEM

Introduction: Previous data suggest neutrophil/lymphocyte ratios (NLRs) could be used as prognostic factor in various solid tumors.

Conference:

Presenting Author: Kolasińska-Ćwikła A

Authors: Ćwikła J, Kolasińska-Ćwikła A, Zrajkowska A, Pałucki J, Seklecka N,

Keywords: Neuroendocrine Tumor, Receptor, Somatostatin, CAPTEM radioligand therapy (RLT), Progression-Free Survival, Neutrophil lymphocyte ratio,

#3819 Dosimetry evaluation in 177Lu-labeled somatostatin receptor analogue therapy

Introduction: Dosimetry reporting in patients receiving PRRT is fundamental to ensure the safety and efficacy of treatment.

Conference:

Presenting Author:

Authors: Cichoński A, Kempińska-Wróbel M, Kolasińska-Ćwikła A, Zrajkowska A, Szarowicz A,

Keywords: radionuclide therapy, dosimetry, lutetium,

#3588 Evaluation of PFS and OS in patients with sporadic, advanced, unresectable, well-differentiated pancreatic neuroendocrine tumors (panNETs) treated initially with Octreotide LAR and methods of further treatment after relapse - Real-world data

Introduction: Evaluation of PFS & OS in patients with sporadic, advanced, unresectable, panNET using first line Octreotide therapy need to be further explored.

Conference:

Presenting Author: Kolasińska-Ćwikła A

Authors: Kolasińska-Ćwikła A, Bednarczuk T, Osowiecka K, Słoniowska A, Roszkowska K,

Keywords: advance, unresectable pancreatic neuroendocrine tumor, initial octreotide LAR therapy, OS, PFS,